Treatment with an inhibitor of 12/15-lipoxygenase, an enzyme elevated in patients with Alzheimer’s disease (AD), reverses cognitive decline and neuropathology in an AD mouse model, reports a new study in Biological Psychiatry. The effects were observed after the AD-like phenotype was already established in the mice, which is promising for its potential therapeutic use, as neuropathology tends to develop many years before the appearance of AD symptoms in patients.
from Dementia Big http://ift.tt/2ifaERB via alcoholic dementia
http://ift.tt/2j8o3L1
No comments:
Post a Comment